Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
Filters
[Clear]
- Price Sensitive: Yes
RJT | Suspension from Official Quotation | PRICE SENSITIVE | 05/02/09 | |
RJT | Confirms no distribution | PRICE SENSITIVE | 18/12/08 | |
RJT | Update | PRICE SENSITIVE | 12/12/08 | |
RJT | Reinstatement to Official Quotation | PRICE SENSITIVE | 01/12/08 | |
RJT | Update | PRICE SENSITIVE | 01/12/08 | |
RJTSuspension from Official Quotation | |||
05/02/09 | PRICE SENSITIVE | 151.99KB | |
RJTConfirms no distribution | |||
18/12/08 | PRICE SENSITIVE | 21.05KB | |
RJTUpdate | |||
12/12/08 | PRICE SENSITIVE | 22.25KB | |
RJTReinstatement to Official Quotation | |||
01/12/08 | PRICE SENSITIVE | 7.09KB | |
RJTUpdate | |||
01/12/08 | PRICE SENSITIVE | 16.75KB | |